Mirena Observational Program

Bayer

Status: Completed

Conditions: Contraception; Estrogen Replacement Therapy; Endometrial Hyperplasia; Menorrhagia

Treatments: Drug: Levonorgestrel (Mirena, BAY86-5028)

Study type: Observational

Funder types: Industry

Identifiers

NCT00883662

14474

MA0910KZ (Other Identifier)

Details and patient eligibility

About

Mirena is used for long-term in Kazakhstan, and in our observational program we would like to study patients distribution per indications of Mirena, and also patient compliance within a year after Mirena insertion. For patients with all approved indications for Mirena use: contraception, treatment of menorrhagia and protection from endometrial hyperplasia during estrogen replacement therapy

Enrollment: 2,725 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications

Exclusion criteria

• All patients with contraindications to Mirena insertion, according to approved prescribing information.

Trial design

2,725 participants in 1 patient group

Group 1

Treatment:

Drug: Levonorgestrel (Mirena, BAY86-5028)